Medical Device Developer Promaxo Adds Life Sciences Executive Dushyant Chipalkatty to Board of Directors
February 27, 2018
Mr. Chipalkatty will apply his extensive operational and strategic leadership experience to help Promaxo bring its MRI clinical prototype to a urology practice this year.
(PRWEB) February 27, 2018
Promaxo, a medical device company that develops and commercializes an office-based MRI with high spatial resolution, has added life sciences executive Dushyant Chipalkatty to its Board of Directors.
Mr. Chipalkatty is the former President of Global Business Development for PACK Pharmaceuticals, which he founded in 2005. He has over three decades of experience in the life sciences field, including senior leadership roles with Morton Grove and Carter-Wallace. He also holds a master's degree in Pharmaceutical Sciences from Rutgers University.
Mr. Chipalkatty will apply his extensive experience in supply chain management, compliance/GMP and manufacturing to help Promaxo achieve key strategic objectives, including bringing the company's MRI clinical prototype to an office-based urology practice this year. Promaxo's single-sided MRI platform, which has successfully generated phantom images, is protected by over 30 issued and pending patents, and has been awarded over $9 million in NIH and NSF grants.
"As a life sciences entrepreneur and a management expert, I am very impressed with the Promaxo technology, business strategy and the management team," stated Dushyant ("Chip") Chipalkatty. "I decided to join the team by investing and contributing as a board member. I am confident that Promaxo has a very bright future, and will significantly improve the quality of medical care."
"Mr. Chipalkatty is an operational guru with extensive expertise in starting and growing lifesciences and healthcare enterprises," stated Promaxo's CEO and President Amit Vohra, PhD, MBA. "We are excited to have him join Promaxo's board, and help us successfully navigate the different stages of growth."
About Promaxo Inc.
Promaxo is developing and commercializing office-based high-resolution MRI, real time MRI compatible biopsy and treatment tools, and CAD software for tissue characterization. The company is currently focused on transforming the screening, diagnosis and treatment of prostate cancer.
For the original version on PRWeb visit: http://www.prweb.com/releases/2018/02/prweb15232006.htm